The 3-year OS and PFS were 83.30% and 87.05% for ALK-negative ALCL, 57.14% and 39.17% for ALK-positive ALCL, 41.67% and 37.50% for AITL, and 28.72% and 15.45% for PTCL-NOS, respectively (Figure 2). The gene discussed is ALK; the disease is anaplastic large cell lymphoma.